Premium
Plasma fibronectin in myeloproliferative disorders and chronic granulocytic leukaemia
Author(s) -
Norfolk D. R.,
Bowen M.,
Roberts B. E.,
Child J. A.
Publication year - 1983
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1983.tb01253.x
Subject(s) - polycythaemia , myelofibrosis , fibronectin , mononuclear phagocyte system , spleen , myeloproliferative disorders , medicine , splenectomy , immunology , endocrinology , chemistry , bone marrow , cell , biochemistry
S ummary . A significant reduction of plasma fibronectin levels was found in polycythaemia vera and myelofibrosis, the lowest levels being found in patients with marked splenomegaly. Plasma fibronectin concentration was normal in essential thrombocythaemia, and only modest reduction was seen in chronic granulocytic leukaemia in either controlled chronic phase or blast cell crisis. In a patient with myelofibrosis, the plasma fibronectin rose from less than 100 mg/l to 177 mg/l after splenectomy. Possible explanations include increased consumption of plasma fibronectin in the expanded mononuclear phagocyte system present in the liver and spleen, reduced hepatic synthesis, and the clearance of circulating immune complexes. Low plasma fibronectin concentrations may increase susceptibility to infection.